Clinical Trials in Austin

Showing 1561-1580 of 15,205 trials

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

NCT07227168

This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a cohort expansion in 1 or more types of cancer to further evaluate a STRO-004 monotherapy dose, determine the best dose for use in later phases, and examine anti-tumor activity. * Part 1C is a dose escalation of STRO-004 combined with pembrolizumab to determine tolerability and preliminary anti-tumor activity of both drugs used together.

Head and Neck Squamous Cell Carcinoma HNSCCNon-Small Cell Lung Cancer NSCLCEsophageal Cancer+6 more

Sutro Biopharma, Inc.200 participantsStarted Nov 2025

Denver, Colorado, United States • Sarasota, Florida, United States • Boston, Massachusetts, United States +3 more locations

Active Not RecruitingPhase 3< 1 mile

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

NCT01349322

RATIONALE: It is not yet know whether higher per daily radiation therapy is equally as effective as standard per daily radiation therapy in treating breast cancer. PURPOSE: This randomized phase III trial studies how well an accelerated course of higher per daily radiation therapy with concomitant boost works compared to standard per daily radiation therapy with a sequential boost in treating patients with early-stage breast cancer that was removed by surgery.

Breast Cancer

Radiation Therapy Oncology Group2,354 participantsStarted May 2011

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Scottsdale, Arizona, United States +412 more locations

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Find Trials by Condition in Austin

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

Patient Reported Symptom Control With THC or CBD Use

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes